Investigative Ophthalmology & Visual Science Cover Image for Volume 65, Issue 7
June 2024
Volume 65, Issue 7
Open Access
ARVO Annual Meeting Abstract  |   June 2024
The use of systemic anti-hypertensive medications affects optic nerve head structural parameters in healthy and glaucoma subjects
Brent A Siesky; Alon Harris; Alice Chandra Verticchio Vercellin; Barbara Wirostko; Gal Antman; Francesco Oddone; Carmela Carnevale; Janet Constance Coleman-Belin; George Eckert; Anna Fabczak-Kubicka; Lukas Ritzer; Rebecca Kellner; Giovanna Guidoboni
Author Affiliations & Notes
  • Brent A Siesky
    Department of Ophthalmology, Icahn School of Medicine at Mount Sinai, New York, New York, United States
  • Alon Harris
    Department of Ophthalmology, Icahn School of Medicine at Mount Sinai, New York, New York, United States
  • Alice Chandra Verticchio Vercellin
    Department of Ophthalmology, Icahn School of Medicine at Mount Sinai, New York, New York, United States
  • Barbara Wirostko
    University of Utah Health John A Moran Eye Center, Salt Lake City, Utah, United States
  • Gal Antman
    Department of Ophthalmology, Icahn School of Medicine at Mount Sinai, New York, New York, United States
    Department of Ophthalmology, Rabin Medical Center, Petah Tikva, Central, Israel
  • Francesco Oddone
    IRCCS-Fondazione Bietti, Rome, Italy
  • Carmela Carnevale
    IRCCS-Fondazione Bietti, Rome, Italy
  • Janet Constance Coleman-Belin
    Department of Ophthalmology, Icahn School of Medicine at Mount Sinai, New York, New York, United States
  • George Eckert
    Department of Biostatistics and Health Data Science, Indiana University School of Medicine, Indianapolis, Indiana, United States
  • Anna Fabczak-Kubicka
    Department of Ophthalmology, Icahn School of Medicine at Mount Sinai, New York, New York, United States
    New York Eye and Ear Infirmary of Mount Sinai, New York, New York, United States
  • Lukas Ritzer
    Department of Ophthalmology, Icahn School of Medicine at Mount Sinai, New York, New York, United States
  • Rebecca Kellner
    Department of Ophthalmology, Icahn School of Medicine at Mount Sinai, New York, New York, United States
  • Giovanna Guidoboni
    Maine College of Engineering and Computing, The University of Maine, Orono, Maine, United States
  • Footnotes
    Commercial Relationships   Brent Siesky None; Alon Harris AdOM, Qlaris, Cipla , Code C (Consultant/Contractor), AdOM, Oxymap, Qlaris, SlitLED , Code I (Personal Financial Interest), AdOM, Qlaris, Code S (non-remunerative); Alice Chandra Verticchio Vercellin None; Barbara Wirostko None; Gal Antman None; Francesco Oddone None; Carmela Carnevale None; Janet Coleman-Belin None; George Eckert None; Anna Fabczak-Kubicka None; Lukas Ritzer None; Rebecca Kellner None; Giovanna Guidoboni Qlaris, Foresite Healthcare LLC, Code C (Consultant/Contractor), Gspace LLC, Code O (Owner)
  • Footnotes
    Support  This work has been partially supported by NIH R01EY030851, NIH R01EY034718, NSF-DMS 2108711/2327640, NYEE Foundation grants, and in part by a Departmental Challenge Grant award from Research to Prevent Blindness, NY.
Investigative Ophthalmology & Visual Science June 2024, Vol.65, 2533. doi:
  • Views
  • Share
  • Tools
    • Alerts
      User Alerts
      You are adding an alert for:
      The use of systemic anti-hypertensive medications affects optic nerve head structural parameters in healthy and glaucoma subjects
      You will receive an email whenever this article is corrected, updated, or cited in the literature. You can manage this and all other alerts in My Account
      The alert will be sent to:
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation
      Citation

      Brent A Siesky, Alon Harris, Alice Chandra Verticchio Vercellin, Barbara Wirostko, Gal Antman, Francesco Oddone, Carmela Carnevale, Janet Constance Coleman-Belin, George Eckert, Anna Fabczak-Kubicka, Lukas Ritzer, Rebecca Kellner, Giovanna Guidoboni; The use of systemic anti-hypertensive medications affects optic nerve head structural parameters in healthy and glaucoma subjects. Invest. Ophthalmol. Vis. Sci. 2024;65(7):2533.

      Download citation file:

      © ARVO (1962-2015); The Authors (2016-present)

      ×
    • Get Permissions
  • Supplements
Abstract

Purpose : To investigate the effects of anti-hypertensive medications on ocular structure in patients with open-angle glaucoma (OAG) and healthy controls.

Methods : 124 OAG patients and 132 non-glaucomatous controls with and without systemic anti-hypertensive medications were categorized into blood pressure (BP) levels based on the American College of Cardiology and American Heart Association guidelines. Categories of systolic BP (SBP) and diastolic BP (DBP) were classified as normal (SBP<120 and DBP<80), elevated (SBP=120–129 and DBP<80), stage 1 hypertension (SBP=130–139 or DBP=80-89), and stage 2 hypertension (SBP≥140 or DBP≥90). Optic nerve head (ONH) parameters, retinal nerve fiber layer (RNFL), and macular thickness were assessed via optical coherence tomography angiography (OCTA, Optovue). Analysis of covariance (ANCOVA) tested strength of interactions among BP category, antihypertensive medication, and study group (OAG/healthy) on structural biomarkers, adjusted for age.

Results : Differences in ONH structural parameters between patients with OAG and controls were significantly reduced in subjects taking anti-hypertensive treatment. Specifically for the same BP category, differences between OAG patients and controls were significantly reduced in healthy subjects receiving anti-hypertensive medications compared to those not receiving treatment (p-value for all interactions:<0.01, Table 1). Use of systemic anti-hypertensive medications did not significantly alter differences in RNFL and macular thickness between patients with OAG and controls within the same BP category (all p>0.05).

Conclusions : In this analysis, use of systemic anti-hypertensive medications reduces differences in OCTA-assessed ONH structural biomarkers between non-glaucomatous controls and patients with OAG.

This abstract was presented at the 2024 ARVO Annual Meeting, held in Seattle, WA, May 5-9, 2024.

 

Image not available
View OriginalDownload Slide
Image not available
View OriginalDownload Slide

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Attribution-NonCommercial-NoDerivatives
Copyright © 2025 Association for Research in Vision and Ophthalmology.
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×
This site uses cookies. By continuing to use our website, you are agreeing to our privacy policy.Accept